The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization

Behavioural Brain Research

Volumn 218, Issue 1, 2011, Pages 194-199

  Riedinger, K ^a   Kulak, A ^a,b,c   Schmidt, W J ^a   von Ameln Mayerhofer, A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

AMPA Kainate receptors; Catalepsy sensitization; Consolidation; Excitatory amino acids; Haloperidol; NMDA receptors

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; AMPA RECEPTOR; DIZOCILPINE; KAINIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BASAL GANGLION; CATALEPSY; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; GLUTAMATERGIC SYSTEM; LATENT PERIOD; MALE; NERVE CELL PLASTICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; BENZODIAZEPINES; CATALEPSY; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HALOPERIDOL; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 78650332080     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.11.055     Document Type: Article

References (72)

1. Sanberg P.R. Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 1980, 284:472-473.
2. Sanberg P.R., Bunsey M.D., Giordano M., Norman A.B. The catalepsy test: its ups and downs. Behav Neurosci 1988, 102:748-759.
3. Blandini F., Nappi G., Tassorelli C., Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. Prog Neurobiol 2000, 62:63-88.
4. Schmidt W.J., Kretschmer B.D. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci Biobehav Rev 1997, 21:381-392.
5. Schmidt W.J., Tzschentke T.M., Kretschmer B.D. State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801. Eur J Neurosci 1999, 11:3365-3368.
6. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 1986, 396:157-198.
7. Stewart J., Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav Pharmacol 1993, 4:289-312.
8. Schmidt W.J., Beninger R.J. Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia. Neurotox Res 2006, 10:161-166.
9. Grillner S., Hellgren J., Menard A., Saitoh K., Wikstrom M.A. Mechanisms for selection of basic motor programs-roles for the striatum and pallidum. Trends Neurosci 2005, 28:364-370.
10. Kropotov J.D., Etlinger S.C. Selection of actions in the basal ganglia-thalamocortical circuits: review and model. Int J Psychophysiol 1999, 31:197-217.
11. Mink J.W. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 1996, 50:381-425.
12. Wiecki T.V., Riedinger K., von Ameln-Mayerhofer A., Schmidt W.J., Frank M.J. A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats: context dependency, extinction, and renewal. Psychopharmacology (Berl) 2009, 204:265-277.
13. Frank M.J., Scheres A., Sherman S.J. Understanding decision-making deficits in neurological conditions: insights from models of natural action selection. Philos Trans R Soc Lond B Biol Sci 2007, 362:1641-1654.
14. Amtage J., Schmidt W.J. Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behav Pharmacol 2003, 14:563-567.
15. Klein A., Schmidt W.J. Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. Behav Pharmacol 2003, 14:49-53.
16. Banjaw M.Y., Mayerhofer A., Schmidt W.J. Anticataleptic activity of cathinone and MDMA (Ecstasy) upon acute and subchronic administration in rat. Synapse 2003, 49:232-238.
17. Abel T., Lattal K.M. Molecular mechanisms of memory acquisition, consolidation and retrieval. Curr Opin Neurobiol 2001, 11:180-187.
18. Inda M.C., Delgado-Garcia J.M., Carrion A.M. Acquisition, consolidation, reconsolidation, and extinction of eyelid conditioning responses require de novo protein synthesis. J Neurosci 2005, 25:2070-2080.
19. Ben Mamou C., Gamache K., Nader K. NMDA receptors are critical for unleashing consolidated auditory fear memories. Nat Neurosci 2006, 9:1237-1239.
20. Contractor A., Swanson G., Heinemann S.F. Kainate receptors are involved in short- and long-term plasticity at mossy fiber synapses in the hippocampus. Neuron 2001, 29:209-216.
21. Cooke S.F., Bliss T.V. Plasticity in the human central nervous system. Brain 2006, 129:1659-1673.
22. Cotman C.W., Monaghan D.T., Ganong A.H. Excitatory amino acid neurotransmission: NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci 1988, 11:61-80.
23. Riedel G., Platt B., Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res 2003, 140:1-47.
24. Sadler R., Herzig V., Schmidt W.J. Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference. Behav Pharmacol 2007, 18:699-703.
25. Sprengel R. Role of AMPA receptors in synaptic plasticity. Cell Tissue Res 2006, 326:447-455.
26. Winters B.D., Bussey T.J. Glutamate receptors in perirhinal cortex mediate encoding, retrieval, and consolidation of object recognition memory. J Neurosci 2005, 25:4243-4251.
27. Bleakman D., Ballyk B.A., Schoepp D.D., Palmer A.J., Bath C.P., Sharpe E.F., et al. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: stereospecificity and selectivity profiles. Neuropharmacology 1996, 35:1689-1702.
28. Paternain A.V., Morales M., Lerma J. Selective antagonism of AMPA receptors unmasks kainate receptor-mediated responses in hippocampal neurons. Neuron 1995, 14:185-189.
29. Vizi E.S., Mike A., Tarnawa I. 2,3-Benzodiazepines (GYKI 52466 and analogs): negative allosteric modulators of ampa receptors. CNS Drug Rev 1996, 2:91-126.
30. Bortolotto Z.A., Lauri S., Isaac J.T., Collingridge G.L. Kainate receptors and the induction of mossy fibre long-term potentiation. Philos Trans R Soc Lond B Biol Sci 2003, 358:657-666.
31. Collingridge G.L., Bliss T.V.P. NMDA receptors-their role in long-term potentiation. Trends Neurosci 1987, 10:288-293.
32. Danysz W., Wroblewski J.T., Costa E. Learning impairment in rats by N-methyl-d-aspartate receptor antagonists. Neuropharmacology 1988, 27:653-656.
33. Rao V.R., Finkbeiner S. NMDA and AMPA receptors: old channels, new tricks. Trends Neurosci 2007, 30:284-291.
34. Boudreau A.C., Wolf M.E. Behavioral sensitization to cocaine is associated with increased AMPA receptor surface expression in the nucleus accumbens. J Neurosci 2005, 25:9144-9151.
35. Sripada S., Gaytan O., Al-rahim S., Swann A., Dafny N. Dose-related effects of MK-801 on acute and chronic methylphenidate administration. Brain Res 1998, 814:78-85.
36. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 1998, 54:679-720.
37. Collingridge G. Synaptic plasticity. The role of NMDA receptors in learning and memory. Nature 1987, 330:604-605.
38. Morris R.G., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature 1986, 319:774-776.
39. Ward L., Mason S.E., Abraham W.C. Effects of the NMDA antagonists CPP and MK-801 on radial arm maze performance in rats. Pharmacol Biochem Behav 1990, 35:785-790.
40. Harder J.A., Aboobaker A.A., Hodgetts T.C., Ridley R.M. Learning impairments induced by glutamate blockade using dizocilpine (MK-801) in monkeys. Br J Pharmacol 1998, 125:1013-1018.
41. Liu J.L., Li M., Dang X.R., Wang Z.H., Rao Z.R., Wu S.X., et al. A NMDA receptor antagonist, MK-801 impairs consolidating extinction of auditory conditioned fear responses in a Pavlovian model. PLoS One 2009, 4:e7548.
42. Colpaert F.C. State dependency as a mechanism of central nervous system drug action. NIDA Res Monogr 1991, 245-266.
43. Overton State-dependent learning produced by depressant and atropine-like drugs. Psychopharmacologia 1966, 6-31.
44. Jackson A., Koek W., Colpaert F.C. NMDA antagonists make learning and recall state-dependent. Behav Pharmacol 1992, 3:415-421.
45. Tzschentke T.M., Schmidt W.J. Blockade of behavioral sensitization by MK-801: fact or artifact? A review of preclinical data. Psychopharmacology (Berl) 2000, 151:142-151.
46. Lanis A., Schmidt W.J. NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent. Behav Pharmacol 2001, 12:143-149.
47. Borta A., Schwarting R.K. Post-trial treatment with the nicotinic agonist metanicotine: differential effects in Wistar rats with high versus low rearing activity. Pharmacol Biochem Behav 2005, 80:541-548.
48. Fricks-Gleason A.N., Marshall J.F. Post-retrieval beta-adrenergic receptor blockade: effects on extinction and reconsolidation of cocaine-cue memories. Learn Mem 2008, 15:643-648.
49. Garg M., Holland H.C. Consolidation and maze learning: the effects of post-trial injections of a depressant drug (pentobarbital sodium). Psychopharmacologia 1968, 12:127-132.
50. McDonald R.J., Hong N.S., Craig L.A., Holahan M.R., Louis M., Muller R.U. NMDA-receptor blockade by CPP impairs post-training consolidation of a rapidly acquired spatial representation in rat hippocampus. Eur J Neurosci 2005, 22:1201-1213.
51. Rose J.K., Rankin C.H. Blocking memory reconsolidation reverses memory-associated changes in glutamate receptor expression. J Neurosci 2006, 26:11582-11587.
52. Danielczyk W. Twenty-five years of amantadine therapy in Parkinson's disease. J Neural Transm Suppl 1995, 46:399-405.
53. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 1997, 21:455-468.
54. Klockgether T., Jacobsen P., Loschmann P.A., Turski L. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm Park Dis Dement Sect 1993, 5:101-106.
55. Kornhuber J., Quack G., Danysz W., Jellinger K., Danielczyk W., Gsell W., et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995, 34:713-721.
56. Uitti R.J., Rajput A.H., Ahlskog J.E., Offord K.P., Schroeder D.R., Ho M.M., et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996, 46:1551-1556.
57. Elliott P.J., Close S.P., Walsh D.M., Hayes A.G., Marriott A.S. Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists. J Neural Transm Park Dis Dement Sect 1990, 2:91-100.
58. Hauber W., Andersen R. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn Schmiedebergs Arch Pharmacol 1993, 348:486-490.
59. Kaur S., Ozer H., Starr M. MK 801 reverses haloperidol-induced catalepsy from both striatal and extrastriatal sites in the rat brain. Eur J Pharmacol 1997, 332:153-160.
60. Papa S.M., Engber T.M., Boldry R.C., Chase T.N. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur J Pharmacol 1993, 232:247-253.
61. Schmidt W.J., Bubser M. Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 1989, 32:621-623.
62. Allen H.L., Iversen L.L. Phencyclidine, dizocilpine, and cerebrocortical neurons. Science 1990, 247:221.
63. Hashimoto K., Fujimura M., Yamagami K. Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment. Life Sci 2000, 66:1071-1078.
64. Hucker H.B., Hutt J.E., White S.D., Arison B.H., Zacchei A.G. Disposition and metabolism of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d] cyclohepten-5,10-imine in rats, dogs, and monkeys. Drug Metab Dispos 1983, 11:54-58.
65. Vezzani A., Serafini R., Stasi M.A., Caccia S., Conti I., Tridico R.V., et al. Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats. J Pharmacol Exp Ther 1989, 249:278-283.
66. O'Hearn E., Molliver M.E. Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine. Neuroscience 2004, 127:373-383.
67. Zadow B., Schmidt W.J. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn Schmiedebergs Arch Pharmacol 1994, 349:61-65.
68. Klockgether T., Turski L., Honore T., Zhang Z.M., Gash D.M., Kurlan R., et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991, 30:717-723.
69. Loschmann P.A., Lange K.W., Kunow M., Rettig K.J., Jahnig P., Honore T., et al. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with l-dopa in models of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1991, 3:203-213.
70. Cools R., Altamirano L., D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006, 44:1663-1673.
71. Frank M.J. Schizophrenia: a computational reinforcement learning perspective. Schizophr Bull 2008, 34:1008-1011.
72. Bowers M.S., Chen B.T., Bonci A AMPA receptor synaptic plasticity induced by psychostimulants: the past, present, and therapeutic future. Neuron 2010, 67:11-24.